Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07138209) titled 'A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma' on Aug. 13.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Qilu Pharmaceutical Co., Ltd.
Condition:
Relapsed or Refractory Multiple Myeloma
Intervention:
Drug: QLS32015
Drug: Pomalidomide
Drug: Selinexor
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 2025
Target Sampl...